

# Nexium

*esomeprazole*

**Gastro-resistant granules for oral suspension 10 mg**

## Composition

Each sachet contains: 10 mg esomeprazole (as magnesium trihydrate). For excipients see section List of excipients.

## Pharmaceutical Form

Gastro-resistant granules for oral suspension

10 mg: Irregularly shaped, pale yellow granules, and white to slightly coloured spherical granules in a unit dose sachet.

## Therapeutic indications

Nexium oral suspension is primarily indicated for GERD in children 1-11 years old.

### *Gastroesophageal Reflux Disease (GERD)*

- treatment of erosive reflux esophagitis
- long-term management of patients with healed esophagitis to prevent relapse
- symptomatic treatment of gastroesophageal reflux disease (GERD)

Nexium oral suspension may also be used by patients having difficulty swallowing dispersed Nexium gastro-resistant tablets. For indications in patients from the age of 12 years reference is made to the Nexium gastro-resistant tablet prescribing information.

## Posology and method of administration

For a 10 mg dose empty the contents of a 10 mg sachet into a glass containing 15 mL of non-carbonated water. For a 20 mg dose empty the contents of two 10 mg sachets into a glass containing 30 mL of non-carbonated water. Stir the contents and leave for a few minutes to thicken. Stir again and drink within 30 minutes. If any material remains after drinking, add more water, stir and drink immediately.

For patients who have a nasogastric or gastric tube in place: see section Instructions for use and handling for preparation and administration instructions.

*Children 1 – 11 years with a bodyweight of  $\geq 10$  kg*

### *Gastroesophageal Reflux Disease (GERD)*

- treatment of erosive reflux esophagitis
- Weight  $\geq 10$ -  $< 20$  kg: 10 mg once daily for

the impact of omeprazole on atazanavir exposure. PPIs including esomeprazole should not be co-administered with atazanavir (see section Contraindications).

### *Drugs metabolised by CYP2C19*

Esomeprazole inhibits CYP2C19, the major esomeprazole metabolising enzyme. Thus, when esomeprazole is combined with drugs metabolised by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin etc., the plasma concentrations of these drugs may be increased and a dose reduction could be needed. This should be considered especially when prescribing esomeprazole for on demand therapy. Concomitant administration of 30 mg esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam.

Concomitant administration of 40 mg esomeprazole resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients. It is recommended to monitor the plasma concentrations of phenytoin when treatment with esomeprazole is introduced or withdrawn. Omeprazole (40 mg once daily) increased voriconazole (a CYP2C19 substrate)  $C_{max}$  and  $AUC_t$  by 15% and 41%, respectively.

Concomitant administration of 40 mg esomeprazole to warfarin-treated patients in a clinical trial showed that coagulation times were within the accepted range. However, post-marketing, a few isolated cases of elevated INR of clinical significance have been reported during concomitant treatment. Monitoring is recommended when initiating and ending concomitant esomeprazole treatment, during treatment with warfarin or other coumarine derivatives.

In healthy volunteers, concomitant administration of 40 mg esomeprazole resulted in a 32% increase in area under the plasma concentration-time curve (AUC) and a 31% prolongation of elimination half-life ( $t_{1/2}$ ) but no significant increase in peak plasma levels of cisapride. The slightly prolonged QTc interval observed after administration of cisapride alone, was not further prolonged when cisapride was given in

8 weeks.

Weight  $\geq 20$  kg: 10 mg or 20 mg once daily for 8 weeks.

- long-term management of patients with healed esophagitis to prevent relapse 10 mg once daily.
- symptomatic treatment of gastroesophageal reflux disease (GERD) 10 mg once daily for up to 8 weeks.

Doses over 1 mg/kg/day have not been studied

#### *Adults and adolescents from the age of 12 years*

For posology in patients from the age of 12 years reference is made to the Nexium gastro-resistant tablet prescribing information.

#### *Children below the age of 1 year*

Nexium should not be used in children younger than 1 year since no data is available.

#### *Impaired renal function*

Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patients with severe renal insufficiency, such patients should be treated with caution. (See section Pharmacokinetic Properties).

#### *Impaired hepatic function*

Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, a maximum dose of 20 mg Nexium should not be exceeded. (See section Pharmacokinetic Properties).

### **Contraindications**

Known hypersensitivity to esomeprazole, substituted benzimidazoles or any other constituents of the formulation. Esomeprazole like other PPIs should not be administered with atazanavir (See section Interactions).

### **Special warnings and precautions for use**

In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with Nexium may alleviate symptoms and delay diagnosis.

Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance.

prolonged use. Esomeprazole was given in combination with esomeprazole.

esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin or quinidine.

Studies evaluating concomitant administration of esomeprazole and either naproxen or rofecoxib did not identify any clinically relevant pharmacokinetic interactions during short-term studies.

#### *Effects of other drugs on the pharmacokinetics of esomeprazole*

Esomeprazole is metabolised by CYP2C19 and CYP3A4. Concomitant administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg b.i.d.), resulted in a doubling of the exposure (AUC) to esomeprazole. Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP 3A4 may result in more than doubling of the esomeprazole exposure. The CYP2C19 and CYP3A4 inhibitor voriconazole increased omeprazole  $AUC_T$  by 280%. A dose adjustment of esomeprazole is not regularly required in either of these situations. However, dose adjustment should be considered in patients with severe hepatic impairment and if long-term treatment is indicated.

### **Pregnancy and lactation**

For Nexium, clinical data on exposed pregnancies are insufficient. With the racemic mixture omeprazole, data on a larger number of exposed pregnancies from epidemiological studies indicate no malformative nor foetotoxic effect. Animal studies with esomeprazole do not indicate direct or indirect harmful effects with respect to embryonal/fetal development. Animal studies with the racemic mixture do not indicate direct or indirect harmful effects with respect to pregnancy, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women.

It is not known whether esomeprazole is excreted in human breast milk. No studies in lactating women have been performed. Therefore Nexium should not be used during breast-feeding.

### **Effects on ability to drive and use machines**

No effects have been observed.

Patients on on-demand treatment should be instructed to contact their physician if their symptoms change in character. When prescribing esomeprazole for on demand therapy, the implications for interactions with other pharmaceuticals, due to fluctuating plasma concentrations of esomeprazole should be considered. (See section Interactions).

This medicinal product contains sucrose and glucose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

## **Interactions**

*Effects of esomeprazole on the pharmacokinetics of other drugs*

*Medicinal products with pH dependent absorption*

The decreased intragastric acidity during treatment with esomeprazole, might increase or decrease the absorption of drugs if the mechanism of absorption is influenced by gastric acidity. In common with the use of other inhibitors of acid secretion or antacids, the absorption of ketoconazole and itraconazole can decrease during treatment with esomeprazole.

Co-administration of omeprazole (40 mg once daily) with atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a substantial reduction in atazanavir exposure (approximately 75% decrease in AUC,  $C_{max}$  and  $C_{min}$ ). Increasing the atazanavir dose to 400 mg did not compensate for

## **Undesirable effects**

The following adverse drug reactions have been identified or suspected in the clinical trials programme for esomeprazole and post-marketing. None was found to be dose-related. The reactions are classified according to frequency (common >1/100, <1/10; uncommon >1/1000, <1/100; rare >1/10000, <1/1000; very rare <1/10000).

*Blood and lymphatic system disorders*

Rare: Leukopenia, thrombocytopenia  
Very rare: Agranulocytosis, pancytopenia

*Ear and labyrinth disorders*

Uncommon: Vertigo

*Eye disorders*

Rare: Blurred vision

*Gastrointestinal disorders*

Common: Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting

Uncommon: Dry mouth

Rare: Stomatitis, gastrointestinal candidiasis

*General disorders and administration site conditions*

Rare: Malaise, increased sweating

*Hepatobiliary disorders*

Uncommon: Increased liver enzymes

Rare: Hepatitis with or without jaundice

Very rare: Hepatic failure, encephalopathy in patients with pre-existing liver disease

*Immune system disorders*

Rare: Hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock

### *Metabolism and nutrition disorders*

Uncommon: Peripheral oedema

Rare: Hyponatraemia

### *Musculoskeletal, connective tissue and bone disorders*

Rare: Arthralgia, myalgia

Very rare: Muscular weakness

### *Nervous system disorders*

Common: Headache

Uncommon: Dizziness, paraesthesia, somnolence

Rare: Taste disturbance

### *Psychiatric disorders*

Uncommon: Insomnia

Rare: Agitation, confusion, depression

Very rare: Aggression, hallucinations

### *Renal and urinary disorders*

Very rare: Interstitial nephritis

### *Reproductive system and breast disorders*

Very rare: Gynaecomastia

### *Respiratory, thoracic and mediastinal disorders*

Rare: Bronchospasm

### *Skin and subcutaneous tissue disorders*

Uncommon: Dermatitis, pruritus, rash, urticaria

Rare: Alopecia, photosensitivity

Very rare: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)

## **Overdose**

There is very limited experience to date with deliberate overdose. The symptoms described in connection with 280 mg were gastrointestinal symptoms and weakness. Single doses of 80 mg esomeprazole were uneventful. No specific antidote is known. Esomeprazole is extensively plasma protein bound and is therefore not readily dialyzable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilised.

## **Pharmacodynamic properties**

Pharmacotherapeutic group: proton pump inhibitor

ATC Code: A02B C05

Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. Both the R- and S-isomer of omeprazole have similar pharmacodynamic activity.

### *Site and mechanism of action*

Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme  $H^+K^+$ -ATPase – the acid pump and inhibits both basal and stimulated acid secretion.

### *Effect on gastric acid secretion*

After oral dosing with esomeprazole 20 mg and 40 mg the onset of effect occurs within one hour. After repeated administration with 20 mg esomeprazole once daily for five days, mean peak acid output after pentagastrin stimulation is decreased 90% when measured 6–7 hours after dosing on day five.

The plasma elimination half-life is about 1.3 hours after repeated once-daily dosing. The pharmacokinetics of esomeprazole has been studied in doses up to 40 mg b.i.d. The area under the plasma concentration-time curve increases with repeated administration of esomeprazole. This increase is dose-dependent and results in a more than dose proportional increase in AUC after repeated administration. This time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by an inhibition of the CYP2C19 enzyme by esomeprazole and/or its sulphone metabolite. Esomeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once-daily administration.

The major metabolites of esomeprazole have no effect on gastric acid secretion. Almost 80% of an oral dose of esomeprazole is excreted as metabolites in the urine, the remainder in the faeces. Less than 1% of the parent drug is found in urine.

### *Special patient populations*

Approximately  $2.9 \pm 1.5\%$  of the population lack a functional CYP2C19 enzyme and are called poor metabolisers. In these individuals the metabolism of esomeprazole is probably mainly catalysed by CYP3A4. After repeated once-daily administration of 40 mg esomeprazole, the mean area under the plasma concentration-time curve was approximately 100% higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were increased by about 60%. These findings have no implications for the posology of esomeprazole.

The metabolism of esomeprazole is not significantly changed in elderly subjects (71–80 years of age).

Following a single dose of 40 mg esomeprazole the mean area under the plasma concentration-time curve is approximately 30% higher in females than in males. No gender difference is seen after repeated once-daily administration. These findings have no implications for the posology of esomeprazole.

The metabolism of esomeprazole in patients with mild to moderate liver dysfunction may be impaired. The metabolic rate is decreased in patients with severe liver dysfunction resulting in a doubling of the area under the plasma concentration-time curve of esomeprazole. Therefore, a maximum of 20 mg should not be exceeded in patients with severe dysfunction.

Esomeprazole or its major metabolites do not show any tendency to accumulate with once-daily dosing.

No studies have been performed in patients with decreased renal function. Since the kidney is responsible for the excretion of the metabolites of esomeprazole but not for the elimination of the parent compound, the metabolism of esomeprazole is not expected to be

After five days after dosing on day five.

After five days of oral dosing with 20 mg and 40 mg of esomeprazole, intragastric pH above 4 was maintained for a mean time of 13 hours and 17 hours, respectively over 24 hours in symptomatic GERD patients. The proportion of patients maintaining an intragastric pH above 4 for at least 8, 12 and 16 hours respectively were for esomeprazole 20 mg 76%, 54% and 24%. Corresponding proportions for esomeprazole 40 mg were 97%, 92% and 56%.

Using AUC as a surrogate parameter for plasma concentration, a relationship between inhibition of acid secretion and exposure has been shown.

#### *Therapeutic effects of acid inhibition*

Healing of reflux esophagitis with esomeprazole 40 mg occurs in approximately 78% of patients after four weeks, and in 93% after eight weeks.

#### *Other effects related to acid inhibition*

During treatment with antisecretory drugs serum gastrin increases in response to the decreased acid secretion.

An increased number of ECL cells possibly related to the increased serum gastrin levels, have been observed in some patients during long term treatment with esomeprazole.

During long-term treatment with antisecretory drugs gastric glandular cysts have been reported to occur at a somewhat increased frequency. These changes are a physiological consequence of pronounced inhibition of acid secretion, are benign and appear to be reversible.

changed in patients with impaired renal function.

#### *Paediatric*

##### *Adolescents 12-18 years:*

Following repeated dose administration of 20 mg and 40 mg esomeprazole, the total exposure (AUC) and the time to reach maximum plasma drug concentration (t<sub>max</sub>) in 12 to 18 year-olds was similar to that in adults for both esomeprazole doses.

##### *Children 1 – 11 years:*

Following repeated dose administration of 10 mg esomeprazole, the total exposure (AUC) was similar within the age range 1 to 11 years and the exposure was similar to the exposure seen with the 20 mg dose in adolescents and adults. The 20 mg dose resulted in higher exposure in 6 to 11 year-olds compared to the same dose in adolescents and adults.

#### **List of excipients**

##### *Esomeprazole granules:*

Glycerol monostearate 40-55, hydroxypropyl cellulose, hypromellose, magnesium stearate, methacrylic acid –ethyl acrylate copolymer (1:1), polysorbate 80, sugar spheres (sucrose and maize starch), talc, triethyl citrate

##### *Excipient granules:*

Citric acid anhydrous, crospovidone, glucose anhydrous, hydroxypropyl cellulose, yellow iron oxide (color E172), xanthan gum

#### **Incompatibilities**

Not applicable

#### **Shelf life**

Please refer to expiry date on outer carton.

## Pharmacokinetic properties

### Absorption and distribution

Esomeprazole is acid labile and is administered orally as enteric-coated granules. *In vivo* conversion to the R-isomer is negligible. Absorption of esomeprazole is rapid, with peak plasma levels occurring approximately 1-2 hours after dose. The absolute bioavailability is 64% after a single dose of 40 mg and increases to 89% after repeated once-daily administration. For 20 mg esomeprazole the corresponding values are 50% and 68%, respectively. The apparent volume of distribution at steady state in healthy subjects is approximately 0.22 L/kg body weight. Esomeprazole is 97% plasma protein bound.

Food intake both delays and decreases the absorption of esomeprazole although this has no significant influence on the effect of esomeprazole on intragastric acidity.

### Metabolism and excretion

Esomeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxy- and desmethyl metabolites of esomeprazole. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of esomeprazole sulphone, the main metabolite in plasma.

The parameters below reflect mainly the pharmacokinetics in individuals with a functional CYP2C19 enzyme, extensive metabolisers.

Total plasma clearance is about 17 L/h after a single dose and about 9 L/h after repeated administration.

## Special precautions for storage

Do not store above 30° C.

## Pack size

Please refer to outer carton for pack size

## Instructions for use and handling (if appropriate)

*For patients who have a nasogastric or gastric tube in place*

For a 10 mg dose add the contents of a 10 mg sachet to a syringe containing 15 mL of water. For a 20 mg dose add the contents of two 10 mg sachets to a syringe containing 30 mL of water. Immediately shake the syringe and leave for a few minutes to thicken. Shake the syringe and inject through the nasogastric or gastric tube within 30 minutes. Refill the syringe with 15 mL of water and shake and flush any remaining contents from the nasogastric or gastric tube into the stomach.

## Date of revision of text:

January 2008

GI.000-135-657.2.0

Nexium is a trade mark of the AstraZeneca group of companies

© AstraZeneca 2008

AstraZeneca AB, Södertälje, Sweden